Digital Health Roundup, March 2021: Record-Breaking Funding; Exec Chats With Medtronic, Edwards LifeSciences
Executive Summary
In this new roundup feature focusing on the most notable developments in digital health, we pick the key news to date.
You may also be interested in...
Lucira Health’s Unexpected Sprint To A First-Of-Its-Kind EUA From FDA: The Inside Story
Lucira Health executive VP Kelly Brezoczky explains in this Medtech Insight case study how the company shifted gears from making a test for influenza A and B to quickly developing one that detected SARS-CoV-2. The result was the company’s COVID-19 All-In-One Test Kit, an at-home prescription molecular diagnostic test that was the first of its type to hit the market when the US FDA granted it emergency use authorization last November.
Ellume CEO Ponders Future Of Company’s Rapid COVID-19 Antigen Test
The developer of the at-home over-the-counter antigen test — the first of its kind to get an emergency use authorization from the FDA – received more than $200m from the government to manufacture in the US. So what’s next for Ellume? In this Medtech Insight case study Q&A, the Australian company’s CEO, Sean Parson, explains.
Analytica Announced Bold Expansion Of Its Pelvic Biofeedback Device
Analytica formed a joint venture with Chinese partners to distribute its PeriCoach system and take advantage of the large Asian urinary incontinence market.